NCT06050122Phase 3Completed

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Study sponsor: Sol-Gel Technologies, Ltd. · SLGL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-08-20Actual
Enrollment · participants113Actual
Source updated2026-09-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 140 participants (planned). After: 113 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2026. After: 20 Aug 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Primary completion date changed

Before: Aug 2026. After: Oct 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview